C Zhu, X Wang, S Wang, J Hu, Y Gao, C Li, J Li, X Wu - Heliyon, 2023 - cell.com
Background Infliximab (IFX) is the first-line treatment for Crohn's disease (CD). However, the
secondary loss of response (LOR) is common in IFX therapy. Therefore, non-invasive …